Provectus Pharmaceuticals Inc. Release: PV-10 Data on Locoregional Disease Control in Metastatic Melanoma to be Presented at European Cancer Congress 2013
6/24/2013 7:31:57 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that an exploratory analysis of data on locoregional disease control in metastatic melanoma from its completed Phase 2 study of intralesional PV-10 has been accepted for presentation at the upcoming European Cancer Congress (ECCO 17- ESMO-38 - ESTRO 32), which will take place September 27 through October 1, 2013 in Amsterdam, The Netherlands.
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter
comments powered by